WO1995025524A1 - UTILISATION DU GINSENOSIDE Ro OU D'UN EXTRAIT VEGETAL EN CONTENANT POUR STIMULER LA SYNTHESE DU COLLAGENE - Google Patents
UTILISATION DU GINSENOSIDE Ro OU D'UN EXTRAIT VEGETAL EN CONTENANT POUR STIMULER LA SYNTHESE DU COLLAGENE Download PDFInfo
- Publication number
- WO1995025524A1 WO1995025524A1 PCT/FR1995/000326 FR9500326W WO9525524A1 WO 1995025524 A1 WO1995025524 A1 WO 1995025524A1 FR 9500326 W FR9500326 W FR 9500326W WO 9525524 A1 WO9525524 A1 WO 9525524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- ginsenoside
- use according
- synthesis
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the Panax come essentially from three countries: - Japan
- the root part is the most frequently used and generally the most active.
- the highest saponin content is observed in the tip of the root (ninjin, in Japanese) and in the rootlets (hairy roots; keninjin, in Japanese).
- the saponins most frequently encountered in plants of the Panax family are of the damarane type.
- saponin ginsenoside R 0 or Chikusetsusaponine V there is a particular saponin ginsenoside R 0 or Chikusetsusaponine V, with oleanane structure, corresponding to the formula below:
- Chikusetsu Ninjin In Japan, P. japonicus is also known as Chikusetsu Ninjin.
- the structure of Chikusetsusaponin V was described in 1971 by: KONDO N., MARUMOTO Y., SHOJI J., Studies on the constituents of Panacis Japonici Rhizoma. IV
- type I collagen represents 80 to 90% of the total skin collagen, the rest consisting mainly of type III collagen, that is to say approximately 10 to 15% of the total skin collagen.
- Type I and type III collagens are very closely associated to form fibers within the dermis (BOREL JP, MONBOISSE JC, CRSoc. Biol. (1993), 187, 124-142; LAPIERE CM., Br. J. Dermatol. (1990), 122, 5-11).
- the fall in the level of cutaneous collagens I and III can also be induced by therapeutic treatments, such as the topical application of glucocorticoids (OIKARINEN A., AUTIO P., KIISTALA U., RISTELLI L., RISTELI J., J. Invest. Dermatol., (1992), 98, 220-225).
- glucocorticoids OIKARINEN A., AUTIO P., KIISTALA U., RISTELLI L., RISTELI J., J. Invest. Dermatol., (1992), 98, 220-225.
- the main object of the present invention is therefore to solve the technical problem consisting in the supply of a new formulation of a cosmetic or pharmaceutical composition, especially a dermatological composition, having good efficacy in preventing or treating the effects of skin aging, as well as on skin firming, or to improve healing.
- the present invention relates to the use of ginsenoside R 0 or a plant extract containing it for the preparation of a cosmetic or pharmaceutical composition, in particular dermatological, intended for stimulating the synthesis of collagen, in particular collagen I and / or collagen III.
- a cosmetic or pharmaceutical composition in particular dermatological, intended for stimulating the synthesis of collagen, in particular collagen I and / or collagen III.
- the above composition is intended to prevent or treat the effects of skin aging, whether of actinic or spontaneous (chronological) origin.
- the above composition is intended to promote the formation of skin support tissues.
- the composition is intended for firming the skin.
- the composition is intended for the healing of skin wounds.
- this plant extract is preferably obtained from Japanese Panax japonicus, Chinese Panax japonicus, Panax japonicus var. Mayor, from Panax japonicus var. Angustifolius, preferably from the roots of these plants.
- the abovementioned extract is obtained by extraction using a polar solvent at reflux such as methanol, from the roots.
- the cosmetic composition which can be used according to the invention is intended to stimulate the synthesis of collagen, in particular that of collagen I and / or collagen III and contains, as active ingredient, a cosmetically effective amount of ginsenoside R 0 or a plant extract containing it.
- composition is intended in particular to promote the synthesis of skin support tissues, to firm the skin and to heal skin wounds. It is therefore particularly intended to combat the effects of skin aging or to obtain skin firming.
- concentrations of ginsenosides R 0 of between 0.001 and 5% by weight relative to the total weight of said composition.
- This concentration will preferably be between 0.001 and 1% by weight relative to the total weight of said composition.
- the composition according to the invention will also contain an extract of Centella asiatica, Asian acid, Madecassic acid or Asiaticoside.
- ginsenoside R 0 or of a plant extract containing it is carried out according to conventional methods allowing both the stimulation of the synthesis of collagen.
- the simplest route of administration is the topical route, especially when looking for the synthesis of skin support tissues, skin tightening and repair of skin injuries.
- ginsenoside R 0 or a plant extract containing it is incorporated in an excipient, vehicle or carrier cosmetically or pharmaceutically, in particular dermatologically, acceptable.
- Such supports are well known to those skilled in the art and also result from examples of cosmetic compositions or pharmaceutical, especially dermatological compositions, described below, which are general in scope.
- the invention relates to the use of ginsenoside R 0 or a plant extract containing it as an agent intended to stimulate the synthesis of collagen I and / or collagen III.
- ginsenoside R 0 or a plant extract containing it as a constituent of a culture medium intended to improve the synthesis of collagen I and / or collagen III in a culture of fibroblasts.
- This agent can be used in any fibroblast culture medium, in particular in a medium where the fibroblasts are included in a matrix, for example in a polymer matrix.
- the invention also relates to a process for stimulating the synthesis of collagen I and / or collagen III consisting in introducing ginsenoside R 0 or a plant extract containing it into a fibroblast culture medium.
- 0.001 to 0.1% of ginsenoside R 0 is preferably introduced into a medium below designated by E 199-C, obtained by introduction of L-glutamine at a concentration of 2 mM / l into an E199 medium marketed. by the company GIBCO.
- the plant extracts containing the ginsenoside R 0 described above can also be used for the preparation of the culture media above.
- Roots of Panax japonicus CA are used. Meyer.
- the residue is reextracted in the soxhlet with 130 ml of methanol for 20 h.
- the 130 ml of methanol are concentrated in vacuo on a rotary evaporator so as to reduce the volume to 45 ml.
- the solution obtained is thrown into 500 ml of anhydrous acetone.
- the beige precipitate obtained is separated by filtration, washed with anhydrous acetone and dried in an oven at 45 ° C.
- Collagen I synthesis is measured with and without treatment on a culture of fibroblasts from a facelift of a 50-year-old woman, using an ELISA method.
- Fibroblast cultures
- the fibroblasts are cultured by the explant method until con ⁇ fluence, at 37 ° C., in a medium consisting of a mixture of medium E 199-C and 10% of fetal calf serum, in an atmosphere saturated with humidity with 5% CO 2 .
- the cells are seeded in 96-well microplates (FALCON) at 10 ⁇ cells per well in medium E 199-C containing 2% serum. After 24 h, this medium is replaced, for a 48 h incubation, by the same medium without serum containing 25 ⁇ M of sodium ascorbate (incubation medium) with or without the products to be tested.
- the products solubilized in DMSO are added to the culture medium at different concentrations.
- the amounts of collagen secreted (mean ⁇ standard deviation) by the treated and untreated cells are compared with a Student's t test.
- the threshold of 0.05 is taken as the level of significance.
- viability is checked by an M.T.T.
- the medium is removed and an M.T.T. is realised.
- the cells are incubated with 100 ⁇ ⁇ of a 0.5 mg / ml solution of a tetrazolium salt in E 199-C medium without phenol red for 3 h at 37 ° C. Then, 100 ⁇ ⁇ Isopropanol are added to each well to dissolve the blue Formazan derivative formed by the mitochondrial succinates dehydrogenases of living cells. The optical density of this solubilized derivative formed is measured at 540 nm.
- the protocol is the same as that described with collagen I except that the ELISA assay is directed against collagen III (Human) and that the duration of treatment of the cultures is 72 h instead of 48 h with collagen I.
- Cosmetic composition promoting the formation of skin support tissues
- Centella asiatica extract 0.4 g
- a powder composed of complex solid particles is prepared by following the process described in French patent FR 2 685 635. This powder has the following composition by weight: - Nylon powder (support particle, consisting of particles with an average diameter of about 20 ⁇ m): 97
- Culture medium promoting the production of collagen by fibroblasts The medium comprises:
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019960705137A KR970701553A (ko) | 1994-03-18 | 1995-03-17 | 콜라겐 합성을 증진시키기 위해 진새노사이드 Ro 또는 진새노사이드 Ro를 함유하는 식물 추출물을 사용하는 방법(USE OF GINSENOSIDE Ro OR A PLANT EXTRACT CONTAINING SAME TO PROMOTE COLLAGEN SYNTHESIS) |
JP7524426A JPH10500395A (ja) | 1994-03-18 | 1995-03-17 | コラーゲン合成を促進するためのジンセノシドr▲下0▼又はこれを含有する植物抽出物の使用 |
EP95914381A EP0751777A1 (fr) | 1994-03-18 | 1995-03-17 | UTILISATION DU GINSENOSIDE R o? OU D'UN EXTRAIT VEGETAL EN CONTENANT POUR STIMULER LA SYNTHESE DU COLLAGENE |
US08/716,363 US5747538A (en) | 1994-03-18 | 1995-03-17 | Use of ginsenoside R0 or a plant extract containing same to promote collagen synthesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9403194A FR2717389B1 (fr) | 1994-03-18 | 1994-03-18 | Utilisation du ginsénoside Ro ou d'un extrait végétal en contenant pour stimuler la synthèse du collagène. |
FR94/03194 | 1994-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995025524A1 true WO1995025524A1 (fr) | 1995-09-28 |
Family
ID=9461193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1995/000326 WO1995025524A1 (fr) | 1994-03-18 | 1995-03-17 | UTILISATION DU GINSENOSIDE Ro OU D'UN EXTRAIT VEGETAL EN CONTENANT POUR STIMULER LA SYNTHESE DU COLLAGENE |
Country Status (7)
Country | Link |
---|---|
US (1) | US5747538A (fr) |
EP (1) | EP0751777A1 (fr) |
JP (1) | JPH10500395A (fr) |
KR (1) | KR970701553A (fr) |
CN (1) | CN1146153A (fr) |
FR (1) | FR2717389B1 (fr) |
WO (1) | WO1995025524A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996019099A2 (fr) * | 1995-08-25 | 1996-06-27 | Lvmh Recherche | Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee |
US6004568A (en) * | 1995-02-17 | 1999-12-21 | Lvmh Recherche | Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract |
EP1005333A1 (fr) * | 1997-02-25 | 2000-06-07 | The University Of Michigan | Procedes et compositions servant a prevenir et a traiter un viellissement de la peau humaine du a l'age |
JP2001517688A (ja) * | 1997-10-01 | 2001-10-09 | エル・ヴェ・エム・アッシュ ルシェルシュ | 化粧品及び皮膚科学におけるエラグ酸及びその誘導体の使用 |
WO2001074327A1 (fr) * | 2000-04-04 | 2001-10-11 | Color Access, Inc. | Composition destinee a ameliorer la barriere lipidique de la peau |
WO2010114191A1 (fr) * | 2009-04-01 | 2010-10-07 | Nonghyupkoreainsam Co., Ltd. | Procédé d'extraction exhaustive pour du ginseng |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2779058B1 (fr) | 1998-05-29 | 2003-02-21 | Dior Christian Parfums | Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique |
US6027728A (en) * | 1998-08-05 | 2000-02-22 | Yuen; Liu | Herbal skin regeneration composition and method |
US6203805B1 (en) | 1998-11-10 | 2001-03-20 | Color Access, Inc. | Topical compositions containing whey proteins |
WO2000051562A1 (fr) * | 1999-03-03 | 2000-09-08 | Shiseido Company, Ltd. | Inhibiteur des metalloproteases matricielles et utilisation associee |
KR100611884B1 (ko) * | 2000-03-10 | 2006-08-11 | 주식회사 엘지생활건강 | 모공 축소 효과가 우수한 화장료 조성물 |
US7326404B2 (en) * | 2000-05-31 | 2008-02-05 | Vuksan Holdings Inc. | Konjac-mannan and ginseng compositions and methods and uses thereof |
US20040185127A1 (en) * | 2001-06-29 | 2004-09-23 | Lerner David S. | Cosmetic composition and method |
CA2414247C (fr) * | 2000-06-29 | 2012-11-27 | Quick-Med Technologies, Inc. | Compose cosmetique constitue d'hydroxamate mmpi et de glucoside triterpenoide et son mode d'utilisation |
US6803215B1 (en) | 2000-11-03 | 2004-10-12 | The Chinese University Of Hong Kong | Sequence characterized amplified region (SCAR) test for the authentication of traditional Chinese medicinal materials |
EP1221325A3 (fr) * | 2001-01-09 | 2003-12-17 | Johnson & Johnson Limited | Composition topique contenant de la centella et du ginseng pour le traitement de blessures sans formation de cicatrices |
DE10121092A1 (de) * | 2001-04-26 | 2002-10-31 | Beiersdorf Ag | Kosmetische oder dermatologische Formulierungen mit einem Gehalt an Sericosid und/oder Pflanzenextrakten, dasselbe enthaltend |
KR100465976B1 (ko) * | 2002-01-05 | 2005-01-13 | 주식회사 태평양 | 나노유화기술에 의해 진세노사이드 f1을 함유하는 미세 유화 입자 및 이를 사용한 피부 외용제 조성물 |
KR100517899B1 (ko) * | 2002-01-30 | 2005-09-30 | 주식회사 일화 | 생물전환 인삼 조성물 및 그 제조 방법 |
CN101601702B (zh) * | 2002-06-25 | 2012-04-18 | 株式会社资生堂 | 抗老化剂 |
US20080076720A1 (en) * | 2003-03-04 | 2008-03-27 | Sancai Xie | Personal care compositions having kinetin or zeatin |
EP1753403B1 (fr) | 2004-05-24 | 2014-08-13 | Takeda Nycomed AS | Particules comprenant un compose contenant du calcium et un alcool de sucre |
WO2006066244A2 (fr) * | 2004-12-17 | 2006-06-22 | Cash Alan B | Procede d'extension de la duree de vie et de retardement de l'apparition de maladies associees au vieillissement |
JP4693623B2 (ja) * | 2005-03-07 | 2011-06-01 | 共栄化学工業株式会社 | 化粧料 |
JP2009500394A (ja) * | 2005-07-08 | 2009-01-08 | ザ プロクター アンド ギャンブル カンパニー | パーソナルケア組成物及び哺乳類の皮膚と毛髪を美化する方法 |
US8048456B2 (en) | 2009-08-28 | 2011-11-01 | Mary Kay Inc. | Skin care formulations |
JP5261457B2 (ja) * | 2010-09-13 | 2013-08-14 | 花王株式会社 | カテプシンd産生促進剤 |
US8895034B2 (en) | 2011-11-02 | 2014-11-25 | Mark K Bennett | Collagen production compound |
KR101877801B1 (ko) * | 2012-07-05 | 2018-07-13 | (주)아모레퍼시픽 | 수경재배 인삼 유래 진세노사이드 f2를 함유하는 피부 외용제 조성물 |
JP2020169139A (ja) * | 2019-04-03 | 2020-10-15 | 共栄化学工業株式会社 | 皮膚外用剤 |
CN111450106A (zh) * | 2020-05-19 | 2020-07-28 | 上海长海医院 | 人参皂苷在修复创面中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2309210A1 (fr) * | 1975-01-27 | 1976-11-26 | Minault Honore | Compositions cosmetiques a base de ginseng et de collagene |
JPS55129228A (en) * | 1979-03-24 | 1980-10-06 | Osaka Chem Lab | Cell-activating agent |
JPS6156114A (ja) * | 1984-08-27 | 1986-03-20 | Kanebo Ltd | 皮膚老化防止用化粧料 |
CN1031023A (zh) * | 1987-08-04 | 1989-02-15 | 周欣初 | 人参抗皱霜及其制作方法 |
JPH04334308A (ja) * | 1991-05-10 | 1992-11-20 | Kanebo Ltd | 皮膚化粧料 |
JPH05262635A (ja) * | 1992-03-19 | 1993-10-12 | Shiseido Co Ltd | 皮膚外用剤 |
FR2695561A1 (fr) * | 1992-09-17 | 1994-03-18 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5626818A (en) * | 1979-08-13 | 1981-03-16 | Osaka Chem Lab | Glucocorticoid drug |
JPH04502167A (ja) * | 1989-10-13 | 1992-04-16 | メダフオール | 長鎖脂肪アルコール誘導体、特に細胞栄養分子及び細胞保護分子としてのその使用、並びに、該誘導体を含有する医薬組成物 |
DE4201179A1 (de) * | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung |
US5564207A (en) * | 1994-02-15 | 1996-10-15 | Flora International Corp. | Placard for curved objects |
-
1994
- 1994-03-18 FR FR9403194A patent/FR2717389B1/fr not_active Expired - Fee Related
-
1995
- 1995-03-17 CN CN95192639A patent/CN1146153A/zh active Pending
- 1995-03-17 KR KR1019960705137A patent/KR970701553A/ko not_active Application Discontinuation
- 1995-03-17 WO PCT/FR1995/000326 patent/WO1995025524A1/fr not_active Application Discontinuation
- 1995-03-17 EP EP95914381A patent/EP0751777A1/fr not_active Withdrawn
- 1995-03-17 JP JP7524426A patent/JPH10500395A/ja active Pending
- 1995-03-17 US US08/716,363 patent/US5747538A/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2309210A1 (fr) * | 1975-01-27 | 1976-11-26 | Minault Honore | Compositions cosmetiques a base de ginseng et de collagene |
JPS55129228A (en) * | 1979-03-24 | 1980-10-06 | Osaka Chem Lab | Cell-activating agent |
JPS6156114A (ja) * | 1984-08-27 | 1986-03-20 | Kanebo Ltd | 皮膚老化防止用化粧料 |
CN1031023A (zh) * | 1987-08-04 | 1989-02-15 | 周欣初 | 人参抗皱霜及其制作方法 |
JPH04334308A (ja) * | 1991-05-10 | 1992-11-20 | Kanebo Ltd | 皮膚化粧料 |
JPH05262635A (ja) * | 1992-03-19 | 1993-10-12 | Shiseido Co Ltd | 皮膚外用剤 |
FR2695561A1 (fr) * | 1992-09-17 | 1994-03-18 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
Non-Patent Citations (10)
Title |
---|
CHEMICAL ABSTRACTS, vol. 115, no. 22, 2 December 1991, Columbus, Ohio, US; abstract no. 239293c, TANAKA H. ET AL.: "Effect of Panax ginseng on the production of glycosaminoglycans in cultured human skin fibroblast" page 464; column 2; * |
CURRI, S. B. ET AL: "Dermocosmetic activity of ginsenosides. Note III: Long-term evaluation of the moisturizing and tonifying effect on the face skin", FITOTERAPIA, 1986, VOL. 57, PAGE(S) 217-22 * |
DATABASE WPI Week 8047, Derwent World Patents Index; AN 80-83353C * |
DATABASE WPI Week 8618, Derwent World Patents Index; AN 86-115969 * |
DATABASE WPI Week 9006, Derwent World Patents Index; AN 90-037334 * |
DATABASE WPI Week 9301, Derwent World Patents Index; AN 93-005487 * |
DATABASE WPI Week 9345, Derwent World Patents Index; AN 93-357127 * |
FRAGRANCE J., vol. 19, no. 8, 1991, pages 90 - 92 * |
GEZZI, A. ET AL: "Dermocosmetic activity of ginsenosides. Note II: Instrumental evaluation of cutaneous hydration and elasticity", FITOTERAPIA, 1986, VOL. 57, PAGE(S) 15-28 * |
LIU CX ET AL: "Recent advances on ginseng research in China.", J ETHNOPHARMACOL (SWITZERLAND), FEB 1992, VOL. 36, NO. 1, PAGE(S) 27-38, * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004568A (en) * | 1995-02-17 | 1999-12-21 | Lvmh Recherche | Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract |
GB2308811B (en) * | 1995-08-25 | 2000-04-05 | Lvmh Rech | Use of vitamin C or derivatives or analogues thereof for promoting skin elastin synthesis |
FR2737971A1 (fr) * | 1995-08-25 | 1997-02-28 | Lvmh Rech | Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee |
GB2308811A (en) * | 1995-08-25 | 1997-07-09 | Lvmh Rech | Use of vitamin C or derivatives or analogues thereof for promoting skin elastic synthesis |
BE1009858A5 (fr) * | 1995-08-25 | 1997-10-07 | Lvmh Rech | Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee. |
US5801192A (en) * | 1995-08-25 | 1998-09-01 | Lvmh Recherche | Use of vitamin C or derivatives or analogues thereof promoting skin elastin synthesis |
ES2129013A1 (es) * | 1995-08-25 | 1999-05-16 | Lvmh Rech | Utilizacion de la vitamina c o de sus derivados o analogos para estimular la sintesis de la elastina cutanea. |
WO1996019099A3 (fr) * | 1995-08-25 | 1997-04-10 | Lvmh Rech | Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee |
WO1996019099A2 (fr) * | 1995-08-25 | 1996-06-27 | Lvmh Recherche | Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee |
EP1005333A1 (fr) * | 1997-02-25 | 2000-06-07 | The University Of Michigan | Procedes et compositions servant a prevenir et a traiter un viellissement de la peau humaine du a l'age |
EP1005333A4 (fr) * | 1997-02-25 | 2001-03-14 | Univ Michigan | Procedes et compositions servant a prevenir et a traiter un viellissement de la peau humaine du a l'age |
US6630516B2 (en) | 1997-02-25 | 2003-10-07 | The Regents Of The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
JP2001517688A (ja) * | 1997-10-01 | 2001-10-09 | エル・ヴェ・エム・アッシュ ルシェルシュ | 化粧品及び皮膚科学におけるエラグ酸及びその誘導体の使用 |
WO2001074327A1 (fr) * | 2000-04-04 | 2001-10-11 | Color Access, Inc. | Composition destinee a ameliorer la barriere lipidique de la peau |
US8710034B2 (en) | 2000-04-04 | 2014-04-29 | Color Access, Inc. | Method and composition for improving skin barrier function |
WO2010114191A1 (fr) * | 2009-04-01 | 2010-10-07 | Nonghyupkoreainsam Co., Ltd. | Procédé d'extraction exhaustive pour du ginseng |
Also Published As
Publication number | Publication date |
---|---|
FR2717389B1 (fr) | 1996-06-07 |
JPH10500395A (ja) | 1998-01-13 |
US5747538A (en) | 1998-05-05 |
KR970701553A (ko) | 1997-04-12 |
EP0751777A1 (fr) | 1997-01-08 |
FR2717389A1 (fr) | 1995-09-22 |
CN1146153A (zh) | 1997-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995025524A1 (fr) | UTILISATION DU GINSENOSIDE Ro OU D'UN EXTRAIT VEGETAL EN CONTENANT POUR STIMULER LA SYNTHESE DU COLLAGENE | |
CA2395283C (fr) | Utilisation d'un extrait d'au moins un vegetal du genre vaccinium comme agent anti-glycation | |
EP0575496B1 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant de l'oxyacanthine, en particulier destinee a stimuler la pousse des cheveux ou a retarder leur chute | |
EP1021161B1 (fr) | Utilisation de l'acide ellagique et de ses derives en cosmetique et en dermatologie | |
EP0660698B1 (fr) | Composition cosmetique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux | |
EP1001740B1 (fr) | Utilisation du ginsenoside rb1 pour stimuler la synthese de l'elastine | |
EP1079797A2 (fr) | Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique | |
EP1003538B1 (fr) | Utilisation d'extraits de polygonatum pour stimuler la synthese de l'elastine cutanee | |
FR2742987A1 (fr) | Utilisation dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie, d'un extrait d'eriobotrya japonica pour stimuler la synthese des glycosaminoglycanes | |
WO2012172199A1 (fr) | Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau | |
EP0946138B1 (fr) | Utilisation d'un extrait de potentilla erecta dans le domaine de la cosmetique et de la pharmacie | |
FR2783425A1 (fr) | Extrait de myrte titre en myrtucommulone b', son procede de preparation et son application en dermatologie et en cosmetologie | |
WO1990006104A1 (fr) | Utilisation du kaempferol et de certains de ses derives pour la preparation d'une composition cosmetique ou pharmaceutique | |
EP0486595B1 (fr) | Utilisation d'un extrait de coleus pour la pigmentation de la peau | |
EP0809484B1 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de bertholletia | |
WO1996020000A1 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique et milieu de culture, contenant un extrait de smelophyllum capense | |
EP0595949B1 (fr) | Compositions pour la pigmentation de la peau ou des cheveux contenant un extrait de marrubium vulgare | |
EP2046356A2 (fr) | Utilisation d'un extrait de gleditsia en cosmétique et en dermatologie | |
FR2700268A1 (fr) | Composition cosmétique ou pharmaceutique, notamment dermatologique, contenant un extrait de Vismia. | |
EP2811977B1 (fr) | Utilisation d'un extrait de feuille de pommier dans une composition cosmetique pour le raffermissement de la peau | |
EP1620116A2 (fr) | Utilisation du quinquina pour la preparation d'un medicament stimulant l'angiogenese | |
WO2023067251A1 (fr) | Composition pour son utilisation dans la synthese cutanee d'acide hyaluronique, dans la reponse immuno-cutanee et une amelioration de la peau | |
FR2828400A1 (fr) | Composition cosmetique ou dermatologique comprenant une association entre de l'igf1 et/ou un compose mimetique de l'igf1, et au moins un retinoide et/ou au moins un derive de retinoide | |
FR3013984A1 (fr) | Composition a usage topique comprenant au moins un extrait de matricaria recutita avec au moins un adn hautement polymerise, et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95192639.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR MX RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08716363 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995914381 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995914381 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995914381 Country of ref document: EP |